American Society of Hematology (ASH) 2020 Virtual meeting key updates in the treatment of CLL

[lankisterguy]

The Virtual 62nd Annual American Society of Hematology (ASH) meeting has showcased key updates in the treatment and management of hematological malignancies. The content of VJHemOnc is intended for healthcare professionals- so these presentations are in "Med-Speak"

Overview of all 20 video summaries here:

vjhemonc.com/event/ash-2020...

-

William Wierda

TRANSCEND CLL 04: 18-month follow up in R/R CLL

vjhemonc.com/video/ps4nfnfr...

-

John Gribben

Umbralisib + ublituximab in CLL

vjhemonc.com/video/ko1rrp5v...

-

Anthony Mato

BRUIN: LOXO-305, a novel BTKi in treated CLL/SLL

vjhemonc.com/video/zdcr7ur6...

-

Tanya Siddiqui

Liso-cel in monotherapy cohort of TRANSCEND

vjhemonc.com/video/_aarkr-k...

-

Len

[Smith123456]

Loxo-305

[Sushibruno in reply to Smith123456]

Are you undergoing this treatment Smith123456?

[Smith123456 in reply to Sushibruno]

no

[Smakwater]

Lots of good news here Len,

The audio qualities improve when forwarding the individual videos over to youtube from vjhemonc.

I wish the U.S would approve the zanabutinib, There is enough data comparatively to do so.

With my limited understanding, it is debatable weather zanabrutinib improves a-optic outcomes over the other BTK inhibitors, however, it does appear that each successive generation of Novel BTK inhibitors targets more precisely and therefore with less adverse events.

JM